gefitinib has been researched along with azomycin in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (azomycin) | Trials (azomycin) | Recent Studies (post-2010) (azomycin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 4,790 | 418 | 1,580 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Binns, D; Cullinane, C; Hicks, RJ; McArthur, GA; Roselt, P; Solomon, B; Weibe, LI | 1 |
| Kunieda, Y; Tominaga, M; Uto, Y; Yamada, H; Yamahana, H | 1 |
2 other study(ies) available for gefitinib and azomycin
| Article | Year |
|---|---|
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorine Radioisotopes; Gefitinib; Humans; Hypoxia; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Oxidation-Reduction; Oxygen; Positron-Emission Tomography; Quinazolines; Tissue Distribution | 2005 |
Development of a novel acetyl glucose-modified gefitinib derivative to enhance the radiosensitizing effect.
Topics: Antineoplastic Agents; Biomedical Enhancement; Cell Line, Tumor; Cell Membrane Permeability; ErbB Receptors; Gefitinib; Glucose; Glucose Transport Proteins, Facilitative; Glycolysis; Humans; Monosaccharide Transport Proteins; Nitroimidazoles; Phosphorylation; Radiation-Sensitizing Agents | 2021 |